IgA Nephropathy: What Is New in Treatment Options?
IgA nephropathy (IgAN), first described in 1968, is one of the most common forms of glomerulonephritis and can progress to end-stage kidney disease (ESKD) in 25 to 30 percent of patients within 20 to 25 years from the onset. It is histologically characterized by mesangial proliferation with prominen...
Saved in:
| Main Authors: | Roberto Scarpioni, Teresa Valsania |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Kidney and Dialysis |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-8236/4/4/19 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lifetime progression of IgA nephropathy: a retrospective cohort study with extended long-term follow-up
by: Mariell Rivedal, et al.
Published: (2025-01-01) -
Efficacy and safety of telitacicept in IgA nephropathy: a real-world study
by: Lingqiu Dong, et al.
Published: (2025-12-01) -
Correlation between serum homocysteine level and clinicopathological factors of IgA nephropathy
by: Cai Xiao-fan, et al.
Published: (2025-01-01) -
Coexistence of anti-glomerular basement membrane disease and IgA nephropathy: an illustrative case and comprehensive literature review
by: Zewei Chen, et al.
Published: (2024-12-01) -
Prognostic role of mesangial IgM deposition in IgA nephropathy: a long-term cohort study
by: Gabriel Stefan, et al.
Published: (2024-12-01)